Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
An Overview of Medical Radiation Countermeasures National REP Conference April 14, 2005 CDR Michael A. Noska, USPHS Senior Health Physicist Center for Devices and Radiological Health Food and Drug Administration U.S. Department of Health and Human Services What this talk is about: Overview of currently approved medical countermeasures Federal programs for countermeasure development Mechanisms for emergency use What this talk is not about: KI DISTRIBUTION!!! Off-label uses Investigational products FDA Regulatory Review IND/IDE NDA/PMA/510K Accelerated approval Bioterrorism Act of 2002 – Emergency Authorization – Animal Rule Potassium Iodide (KI) Prophylaxis against uptake of *I Dosing – – – – – – Supplied as 65 or 130 mg tablet >40 yo, >500 rem: 130 mg/day 18-40, >10 rem: 130 mg/day 3-18 yo, preg/lact: 65 mg/day 1 mo-3 yo: 32 mg/day Birth to 1 mo: 16 mg/day Bioterrorism Act Shelf-life extension Prussian Blue (Radiogardase™) Radioeliminator for *Cs and Tl – Binds and reduces GI re-absorption Dosing – Supplied as 500 mg tablet – Adult: 3 g three times a day for 30 days – Children 2-12 yo: 1 g three times a day for 30 days Routes of administration Side effects: gastric distress DTPA Increases rate of elimination of certain transuranics (Pu, Am, Cm) Ca and Zn analogs Dosing – Supplied as clear sterile liquid for injection – Adult: 1 g Ca first day + 1 g Ca/Zn following – Pediatric (<12 yo): 14 mg/kg Ca; 14 mg/kg Ca/Zn Routes of administration – IV – Nebulizer – RFI for oral Ancillary topics Cytokines (Biological response modifiers) – Neupogen Strategic National Stockpile (SNS) Medical Countermeasure Development HSC/OSTP RDD/IND Working Group – Medical Countermeasures Sub-group DHS/S&T Interagency WG NIH/NIAID Centers of Excellence HHS/Project Bioshield Act of 2004 grants for focused product development FDA Inter-Center WG on MCM Contact Information FDA www.fda.gov www.fda.gov/oc/opacom/hottopics/bioterrorism.html FDA Emergency Operations Center 301-443-1240, 800-759-8352 Mike Noska, CDRH/OCER/DMQRP/RPB 301-594-3527 [email protected]